Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
PDF) Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners
Cleopatra trial
Medicines | Free Full-Text | The Changing Landscape of Breast Cancer: How Biology Drives Therapy | HTML
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study - ESMO Open
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. | Semantic Scholar
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
CLEOPATRA: Survival With Dual HER2 Blockade 'Unprecedented' - The ASCO Post
Confirmatory Overall Survival Analysis of CLEOPATRA | Research To Practice
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Semantic Scholar
Nadine Ezer Clinical Trial Monitor Roche - ppt download
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Oncology
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial - European Journal of Cancer
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer - Annals of Oncology
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer | NEJM
Real-World Analysis of THP in mBC Shows Similar Survival, Safety Outcomes to CLEOPATRA Trial
Expert Guidance on Selecting Treatment and Management Approaches in Metastatic Breast Cancer Jointly sponsored by the Annenberg Center for Health Sciences. - ppt download
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - The Lancet Oncology
Pertuzumab with Trastuzumab and Docetaxel in Elderly Patients in the CLEOPATRA Study | Research To Practice
End-of-Study Results From CLEOPATRA - The ASCO Post
Summary of the CLEOPATRA, APHINITY, NeoSphere, and TRYPHAENA clinical... | Download Scientific Diagram
HER2-positive advanced breast cancer treatment in 2020 - Cancer Treatment Reviews
CLEOPATRA: Pertuzumab Ups Survival by 16 Months in HER2-Positive Breast Cancer
